The invention relates to pharmacology, medicine, veterinary medicine and to the pharmaceutical industry, in particular to a process for preparing original composite antimicrobial preparations for parenteral administration which have increased therapeutic effectiveness in the treatment of severe forms of infectious and inflammatory diseases. The proposed pharmaceutical compositions comprise, as active ingredient, beta-lactam antibiotics and highly disperse nanostructured silicon dioxide in ratios of from 10:1 to 75:1 by weight, respectively. The silicon dioxide particles present in the composition are the means of supplying the molecules of the antibiotics to the phagocytes, which makes it possible to increase, in a targeted manner, the concentration of the antimicrobial preparations in the areas of inflammation and to substantially neutralize the phenomenon of antibiotic resistance of microorganisms. The claimed process for preparing a pharmaceutical composition consists in mixing a beta-lactam antibiotic substance with highly disperse nanostructured silicon dioxide and is characterized in that the mixture of the above-mentioned substances in ratios of from 10:1 to 75:1 by weight, respectively, is subjected to mechanical processing by means of impact abrasion until the proportion by weight of the finely disperse fraction (<； 5 µm) is increased to at least 25%. The resultant mixture is used for preparing injection solutions.本発明は、薬理学、医薬、獣医学及び医薬産業に関する。本発明は、具体的には重い感染および炎症性疾患の場合により高い治療効率を有する新規の複数成分を含む外用抗菌性薬剤の製造方法に関する。提供する医薬組成物の活性物質は、β－ラクタム抗生物質とナノ構造を有する微細分散二酸化ケイ素であり、これらは１０：１～７５：１の質量比を有する。二酸化ケイ素粒子は、抗生物質分子を食細胞に送達し、それにより炎症領域における抗菌性薬剤濃度を高め、微生物の抗生物質耐性を顕著に減少させることができる。医薬組成物の製造方法は、β－ラクタム抗生物質を微細分散ナノ構造二酸化ケイ素と混合することを含む。主な特徴は、微粉末分画（５μｍ未満）の質量比が２５％以上に高くなるまで、１０：１～７５：１の質量比を有する前述物質の混合物を衝撃磨砕作用で機械処理することである。こうして得られた混合物は、注射用薬剤に用いられる。【選択図】なし
